cvot tirzepatide SURPASS-CVOT: Tirzepatide Significantly Reduces Major Kidney Events Compared to Dulaglutide in T2D

Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes

20.01

★★★★☆4.8 (126)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

29.18

★★★★★4.9 (98)

An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists

29.10

★★★★★5.0 (157)

SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes

22.05

★★★★★4.7 (84)

Original Article: Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes (SURPASS-CVOT)

21.64

★★★★★4.9 (203)

SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized

24.27

★★★★★5.0 (176)

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics

25.72

★★★★★4.8 (132)